TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.

MLA

Miki, Shunichiro, et al. “TERT Promoter C228T Mutation in Neural Progenitors Confers Growth Advantage Following Telomere Shortening in Vivo.” Neuro-Oncology, vol. 24, no. 12, Dec. 2022, pp. 2063–75. EBSCOhost, https://doi.org/10.1093/neuonc/noac080.

APA

Miki, S., Koga, T., Mckinney, A. M., Parisian, A. D., Tadokoro, T., Vadla, R., Marsala, M., Hevner, R. F., Costello, J. F., & Furnari, F. (2022). TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo. Neuro-Oncology, 24(12), 2063–2075. https://doi.org/10.1093/neuonc/noac080

Chicago

Miki, Shunichiro, Tomoyuki Koga, Andrew M Mckinney, Alison D Parisian, Takahiro Tadokoro, Raghavendra Vadla, Martin Marsala, Robert F Hevner, Joseph F Costello, and Frank Furnari. 2022. “TERT Promoter C228T Mutation in Neural Progenitors Confers Growth Advantage Following Telomere Shortening in Vivo.” Neuro-Oncology 24 (12): 2063–75. doi:10.1093/neuonc/noac080.